We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 129.22 | 0 | 09:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. Thursday said Kenneth Frazier, its chairman and chief executive, will retire as CEO at the end of June.
The Kenilworth, N.J., drug maker said Robert Davis, currently executive vice president of global services and chief financial officer, will succeed Mr. Frazier as CEO, effective July 1.
Merck said Mr. Davis, who joined as chief financial officer in 2014, will become president on April 1, at which time the company's four operating divisions will begin reporting to him.
Merck said Mr. Frazier, who joined the company in 1992, will remain as executive chairman for a transition period to be determined by the board. Mr. Frazier has been Merck's CEO since January 2011 and chairman since December 2011.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 04, 2021 07:16 ET (12:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
